Search review questions

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · psychiatric patients (schizophrenia or schizoaffective disorder) with antipsychotic‐induced tardive dyskinesia

Tardive dyskinesia: no clinically important improvement · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia

Tardive dyskinesia: deterioration of symptoms ‐ not reported · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia

Global state: Not improved or worsened ‐ medium termDichotomised Montgomery‐Asberg Depression Rating Scale (MDRS) · patients with Schizophrenia

Global state: Relapse ‐ long termClinical judgement · patients with Schizophrenia

Adverse effects: Death ‐ long termOccurrences of death · patients with Schizophrenia

Adverse effects: Extrapyramidal effects (akathisia) ‐ short termInstances of akathisia · patients with Schizophrenia

Adverse effects: Extrapyramidal effects (rigidity) ‐ short termInstances of rigidity · patients with Schizophrenia

Global state: 1a. Relapse ‐ long term · people with schizophrenia

Global state: 2. Clinically important change (no improvement) ‐ long term · people with schizophrenia

Mental state: General ‐ clinically important change (no improvement) ‐ long term · people with schizophrenia

Adverse events: General: any adverse event · people with schizophrenia

Functioning: Social (average endpoint score SOFAS, high = good) ‐ long term · people with schizophrenia

Quality of life: General (average endpoint score QLS, high = good) ‐ long term * · people with schizophrenia

Satisfaction with treatment: 1. Leaving the study early ‐ long term · people with schizophrenia

Tranquillisation or asleep · psychosis‐induced aggression or agitation (rapid tranquillisation)

Global state: non‐responders to the first injection · psychosis‐induced aggression or agitation (rapid tranquillisation)

Adverse effects: one or more adverse events during 24 hours (only reported if occurred in ≥ 5% of people) · psychosis‐induced aggression or agitation (rapid tranquillisation)

Adverse effects: movement disorders ‐ EPS during 24 hours (only reported if occurred in ≥ 5% of people) · psychosis‐induced aggression or agitation (rapid tranquillisation)

Economic outcomes · psychosis‐induced aggression or agitation (rapid tranquillisation)

Tranquillisation or asleep · psychosis‐induced aggression or agitation (rapid tranquillisation)

Repeated need for tranquillisation · psychosis‐induced aggression or agitation (rapid tranquillisation)

Specific behaviour: Agitation ‐ clinically important change (PANSS ‐EC reduction ≥ 40% from baseline) ‐ up to 2 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)

Global state: CGI‐S change score up to 2 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)

Adverse effects: one or more adverse effects during 24 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)

Adverse effects: somnolence during 24 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)

Repeated need for tranquillisation ‐ needing additional injections during 24 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)

Economic outcomes · psychosis‐induced aggression or agitation (rapid tranquillisation)

Specific behaviour: Agitation ‐ clinically important change (PANSS ‐EC reduction ≥ 40% from baseline) ‐ up to 2 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)

Global state: non‐responders to the first injection · psychosis‐induced aggression or agitation (rapid tranquillisation)

Adverse effects: one or more adverse events during 24 hours (only reported if occurred in ≥ 5% of people) · psychosis‐induced aggression or agitation (rapid tranquillisation)

Economic outcomes · psychosis‐induced aggression or agitation (rapid tranquillisation)

Tranquillisation or asleep · psychosis‐induced aggression or agitation (rapid tranquillisation)

Repeated need for tranquillisation ‐ needing additional injections during 24 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)

Specific behaviour: Agitation ‐ clinically important change (PANSS ‐EC reduction ≥ 40% from baseline) ‐ up to 2 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)

Global state: relapse · people with schizophrenia

Global state: rehospitalisation* · people with schizophrenia

Mental state: General ‐ clinically important change (no improvement) · people with schizophrenia

Adverse effect/event: death ‐ any cause · people with schizophrenia

Functioning ‐ average scores (Social Functioning Scale, high = good) · people with schizophrenia

Quality of life: average scores (MSQOL, high = good, medium term) · people with schizophrenia

Satisfaction with treatment ‐ leaving the study early for any reason · people with schizophrenia

Tranquillisation or asleep by 30 minutes ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation)

Global outcome: need for additional measures · psychosis‐induced aggression or agitation (rapid tranquillisation)

Adverse effects: movement disorder · psychosis‐induced aggression or agitation (rapid tranquillisation)

Economic outcomes ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation)

Tranquillisation or asleep by 30 minutes ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation)

Repeated need for tranquillisation within 24 hours ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation)

Specific behaviour ‐ aggression, over 24 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)

Global outcome ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation)